Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats

Diabetologia

Volumn 42, Issue 11, 1999, Pages 1324-1331

  Balkan, B ^b   Kwasnik, L ^c   Miserendino, R ^c   Holst, J J ^a   Li, X ^c  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^c NONE

Author keywords

DPP IV; Gastric emptying; GLP 1; Insulin secretion; NVP DPP728

Indexed keywords

1 [2 [(CYANOPYRIDIN 2 YL)AMINO]ETHYLAMINO]ACETETYL 2 CYANO PYRROLIDINE; 6 [[2 [[2 (2 CYANO 1 PYRROLIDINYL) 2 OXOETHYL]AMINO]ETHYL]AMINO]NICOTINONITRILE; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME INHIBITION; IMPAIRED GLUCOSE TOLERANCE; INSULIN RELEASE; INSULIN RESPONSE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; ORAL DRUG ADMINISTRATION; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT;

ANIMALS; ANTIGENS, CD26; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDES; GLUCOSE; GLUCOSE TOLERANCE TEST; MALE; NITRILES; OBESITY; OSMOLAR CONCENTRATION; PEPTIDE FRAGMENTS; PYRROLIDINES; RATS; RATS, ZUCKER; REFERENCE VALUES;

EID: 0000135759     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001250051445     Document Type: Article

References (48)

1. 1. Creutzfeldt W (1979) The incretin concept today. Diabetologia 16: 75-85
2. 2. Brown JC, Buchan AM, McIntosh CH, Pederson RA (1989) Gastric inhibitory polypeptide. Schultz S.G., Makhlouf, G.M., and Rauner, B.B. Handbook of Physiology, Section 6. Bethesda, American Physiological Society, pp 403-430
3. 3. Holst JJ (1997) Enteroglucagon. Annu Rev Physiol 59: 257-271
4. 4. Goeke R, Wagner B, Fehmann HC, Goeke B (1993) Glucose-dependency of the insulin stimulatory effect of glucagon-like peptide-1 (7-36) amide on the rat pancreas. Res Exp Med (Berl) 193: 97-103
5. 5. Fridolf T, Bottcher G, Sundler F, Ahren B (1991) GLP-1 and GLP-1(7-36) amide: influences on basal and stimulated insulin and glucagon secretion in the mouse. Pancreas 6: 208-215
6. 6. Lu M, Wheeler MB, Leng XH, Boyd AE 3rd (1993) The role of the free cytosolic calcium level in beta-cell signal transduction by gastric inhibitory polypeptide and glucagon-like peptide I(7-37). Endocrinology 132: 94-100
7. 7. Fehmann HC, Goeke R, Goeke B, Bachle R, Wagner B, Arnold R (1991) Priming effect of glucagon-like peptide-1 (7-36) amide, glucose-dependent insulinotropic polypeptide and cholecystokinin-8 at the isolated perfused rat pancreas. Biochim Biophys Acta 1091: 356-363
8. 8. Kolligs F, Fehmann HC, Goke R, Goke B (1995) Reduction of the incretin effect in rats by the glucagon-like peptide 1 receptor antagonist exendin (9-39) amide. Diabetes 44: 16-19
9. 9. Wang Z, Wang RM, Owji AA, Smith DM, Ghatei MA, Bloom SR (1995) Glucagon-like peptide-1 is a physiological incretin in rat. J Clin Invest 95: 417-421
10. 10. D'Alessio DA, Vogel RL, Prigeon RL et al. (1996) Elimination of the action of Glucagon-like Peptide 1 causes an impairment of glucose tolerance after nutrient ingestion in healthy baboons. J Clin Invest 97: 133-138
11. 11. Seltzer HS, Allen EW, Herron AL, Brennan MT (1998) Insulin secretion in response to glycemic stimulus: relation of delayed initial release to carbohydrate intolerance in mild diabetes mellitus. J Clin Invest 46: 323-335
12. 12. Bruce DG, Chisholm DJ, Storlien LH, Kraegen EW (1988) Physiological importance of deficiency in early prandial insulin secretion in non-insulin-dependent diabetes. Diabetes 37: 736-744
13. 13. Groop PH, Melander A, Groop LC (1993) The relationship between early insulin release and glucose tolerance in healthy subjects. Scand J Clin Lab Invest 53: 405-409
14. 14. Willms B, Werner J, Holst JJ, Oerskov C, Creutzfeldt W, Nauck MA (1996) Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon - like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients. J Clin Endocrinol Metab 81: 327-332
15. 15. Gutniak MK, Linde B, Holst JJ, Efendic S (1994) Subcutaneous injection of the incretin hormone glucagon-like peptide 1 abolishes postprandial glycemia in NIDDM. Diabetes Care 17: 1039-1044
16. 16. Ritzel U, Orskov C, Holst JJ, Nauck MA (1995) Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 (7-36 amide) after subcutaneous injection in healthy volunteers. Dose-response-relationships. Diabetologia 38: 720-725
17. 17. Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W (1993) Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (noninsulin-dependent) diabetic patients. Diabetologia 36: 741-744
18. 18. Ahren B, Larsson H, Holst JJ (1997) Effects of glucagon-like peptide-1 on islet function and insulin sensitivity in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 82: 473-478
19. 19. Rachman J, Barrow BA, Levy JC, Turner RC (1997) Near-normalization of diurnal glucose concentrations by continuous administration of glucagon - like peptide-1 (GLP-1) in subjects with NIDDM. Diabetologia 40: 205-211
20. 20. Drucker DJ (1998) Glucagon-like peptides. Diabetes 47: 159-169
21. 21. Gutniak M, Larsson H, Heiber M, Juneskans, OT, Holst JJ, Ahren B (1996) Potential therapeutic levels of glucagon-like peptide 1 achieved in humans by a buccal tablet. Diabetes Care 19: 843-848
22. 22. Deacon CF, Johnsen AH, Holst JJ (1995) Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 80: 952-957
23. 23. Deacon CF, Pridal L, Klarskov L, Olesen M, Holst JJ (1996) Glucagon - like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig. Am J Physiol 271: (Pt. 1), E458-E464
24. 24. Holst JJ , Hansen L, Orskov C, Wojdemann M, Wettergren A, Deacon CF (1998) GLP-1 (7-36 amide) is transformed by dipeptidyl peptidase IV in the capillaries supplying the L-cells into GLP-1 (9-36 amide), which antagonizes the gastrointestinal effects of GLP-1. Diabetes 47:A30
25. 25. Nauck MA, Wollschlaeger D, Werner J et al. (1996) Effects of subcutaneous glucagon - like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM. Diabetologia 39: 1546-1553
26. 26. Hughes TE, Mone MD, Russell ME, Weldon SC, Villhauer EB (1999) NVP-DPP728 (1-[2-[(5-cyanopyridin-2-yl)amikno]ethylamino]acetyl-2-cyano-(S)-pyrrolidine), a slow-binding inhibitor of dipeptidyl peptidase IV. Biochemistry (in press)
27. 27. Orskov C, Rabenhoj L, Wettergren A, Kofod H, Holst JJ (1994) Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes 43: 535-539
28. 28. Orskov C, Jeppesen J, Madsbad S, Holst JJ (1991) Proglucagon products in plasma of noninsulin-dependent diabetics and non-diabetic controls in the fasting state and after oral glucose and intravenous arginine. J Clin Invest 87: 415-423
29. 29. Deacon CF, Hughes TE, Holst JJ (1998) Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig. Diabetes 47: 764-769
30. 30. Kubota T, Flentke GR, Bachovchin WW, Stollar BD (1992) Involvement of dipeptidyl peptidase IV in an in vivo immune response. Clin Exp Immunol 89: 192-197
31. 31. Holst JJ, Deacon CF (1998) Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type II diabetes mellitus. Diabetes 47: in press
32. 32. Porte D Jr (1991) Banting Lecture 1990: B-Cells in Type II Diabetes Mellitus. Diabetes 40: 166-180
33. 33. Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W (1993) Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 91: 301-307
34. 34. Kieffer TJ, McIntosh CH, Pederson RA (1995) Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 136: 3585-3596
35. 35. Wettergren A, Wojdemann M, Holst JJ (1998) The inhibitory effect of glucagon-like peptide-1 (7-36)amide on antral motility is antagonized by its N-terminally truncated primary metabolite GLP-1 (9-36)amide. Peptides 19: 877-882
36. 36. Knudsen LB, Pridal L (1996) Glucagon - like peptide-1-(9-36) amide is a major metabolite of glucagon - like peptide - 1 -(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor. Eur J Pharmacol 318: 429-435
37. 37. Chua SC Jr, White DW, Wu-Peng XS et al. (1996) Phenotype of fatty due to Gln269Pro mutation in the leptin receptor (Lepr). Diabetes 45: 1141-1143
38. 38. Brozinick JT Jr, Etgen GJ Jr, Yaspelkis BB 3rd, Ivy JL (1994) Glucose uptake and GLUT-4 protein distribution in skeletal muscle of the obese Zucker rat. Am J Physiol 267:R236-R243
39. 39. Brozinick JT Jr, Etgen GJ Jr, Yaspelkis BB 3rd, Kang HY, Ivy JL (1993) Effects of exercise training on muscle GLUT-4 protein content and translocation in obese Zucker rats. Am J Physiol 265: E419-E427
40. 40. Penicaud L, Ferre P, Assimacopoulos JF et al. (1991) Increased gene expression of lipogenic enzymes and glucose transporter in white adipose tissue of suckling and weaned obese Zucker rats. Biochem. J 279: 303-308
41. 41. Hatanaka S, Kondoh M, Kawarabayashi K, Furuhama K (1994) The measurement of gastric emptying in conscious rats by monitoring serial changes in serum acetaminophen level. J Pharmacol Toxicol Methods 31: 161-165
42. 42. Sanaka M, Koike Y, Yamamoto T et al. (1997) A reliable and convenient parameter of the rate of paracetamol absorption to measure gastric emptying rate of liquids. Int J Clin Pharmacol Ther 35: 509-513
43. 43. Schirra J, Katschinski M, Weidman C et al. (1996) Gastric emptying and release of incretin hormones after glucose ingestion in humans. J Clin Invest 97: 92-103
44. 44. Young AA, Gedulin, BR, Rink TJ (1996) Dose-responses for the slowing of gastric emptying in a rodent model by glucagon-like peptide (7-36) NH2, amylin, cholecystokinin, and other possible regulators of nutrient uptake. Metabolism 45: 1-3
45. 45. Balkan B, Kwasnik L, Miserendino R, Li X (1998) Effects of DPP-IV inhibition on oral glucose tolerance - Comparison with GLP-1 and GIP injections (Abstract). -34th Ann. Meeting of the European Association for the Study of Diabetes, Pancreatic β-cell and islet research 1998-EASD Islet Study Group, S'Agaro, Girona, September 13-14, 1998. Endocrinologia 45: 269
46. 46. Balkan B, Kwasnik L, Miserendino R, Mone M, Hughes TE, Li X (1997) Improved insulin secretion and oral glucose tolerance after In vivo inhibition of DPP-IV in obese Zucker rats. 16th International Diabetes Federation Congress, Helsinki, Finland, July 20-25, 1997. Diabetologia 40: 511, A131 (Abstract)
47. 47. Pederson RA, White HA, Schlenzig D, Pauly RP, McIntosh CHS, Demuth H-U (1998) Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidylpeptidase IV inhibitor isoleucine thiazolidide. Diabetes 47: 1253-1258
48. 48. Mentlein R, Gallwitz B, Schmidt WE (1993) Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 214: 829-835